10. Références

1. Division de la santé de Statistique Canada. Données inédites.

2. Kannel, W.D., Gagnon, D.R., et Cupples, L.A. Epidemiology of sudden coronary death: Population at risk. Canadian Journal of Cardiology, 1990; 6:439-444.

3. Wannamethee, G., Shaper, MacFarlane, P.W., et Walker, M. Risk factors for sudden cardiac death in middle-aged British men. Circulation, 1995; 91:1749-1756.

4. Dagenais, G.R., Cantin, B., Dagenais, F., et coll. Importance of outside hospital mortality as a first acute ischemic heart event: The Quebec Cardiovascular Study. Canadian Journal of Cardiology, 1996; 12:914-918.

5. Naylor, C.D. et Chen, E. Population-wide mortality trends among patients hospitalized for acute myocardial infarction: The Ontario experience, 1981-1991. Journal of American College of Cardiology, 1994; 24:1431-1438.

6. Rogers, W.J., Bowlby, L.J., Chandra, N.A., et coll. Treatment of myocardial infarction in the United States (1990 to 1993): Observations from the national registry of myocardial infarction. Circulation , 1994; 90:2103-2114.

7. Johansen, H., Nair, C, et Taylor, G. Person-based information for acute myocardial infarction (AMI) from 1992/93 Canadian hospital discharge data with projections to the year 2016. Manuscrit inédit.

8. Rouleau, J. L., Talajic, M., Sussex, B., et coll. Myocardial infarction patients in the 1990's - their risk factors, stratification and survival in Canada: The Canadian Assessment of Myocardial Infarction(CAMI) Study. Journal of American College of Cardiology, 1996; 27:1119-27.

9. Figuerdo, V.M., Amidon, T.M., et Wolfe, C.L. Thrombolysis after acute myocardial infarction: who should be added to inclusion criteria: Postgraduate Medicine, décembre 1994; 96(8):30-4, 37-40.

10. Fowles, R.E. Myocardial infarction in the 1990's. The importance of early thrombolysis therapy. Postgraduate Medicine, mai 1995; 97(5):135-8,141-2,145-6.

11. Alpert, J.S. (réd.) Cardiology for the Primary Care Physician . St. Louis, Mosby, 1996 pp.153.

12. Alpert, J.S. (réd). Cardiology for the Primary Care Physician . St. Louis, Mosby, 1996, pp.154.

13. Cox, J.L., Lee, E., Langer, A., et coll. Time to treatment with thrombolysis therapy: determinants and effect on short-term non-fatal outcomes of acute myocardial infarction. Canadian Medical Association Journal , 1997; 156:497-505.

14. Lee, K.L., Califf, R.M., Simes, J., et coll. Holding GUSTO up to the light. Annals of Internal Medicine, 1994; 120:876-881.

15. Ridker, P.M., O'Donnell, C.J., Marder, V., et coll. A response to "Holding GUSTO up to the light". Annals of Internal Medicine, 1994; 120:882-885.

16. Cairns, J., et coll. Canadian Consensus Conference on Coronary Thrombolysis - 1994 Update. Canadian Journal of Cardiology, 1994; 10:517-521.

17. Canadian Consensus Conference on Coronary Thrombolysis - 1994 Recommendations. Canadian Journal of Cardiology , 1994; 10:522-528.

18. Hanes, D.S., Weir, M.R. et Sowers, J.R. Gender considerations in hypertension pathophysiology and treatment. American Journal of Medicine, 1996; 101(3A):10S-21S.

19. Johansen, H.L., Nargundkar, M., Nair, C., et coll. Women and cardiovascular disease. Chronic Diseases in Canada, 1990; 11(3):41-46.

20. Mao, Y., Morrison, H., Semenciew, R., et Wigle, D. Mortality on Canadian Indian Reserves - 1977-82. Canadian Journal of Public Health, 1986 ;77:263-268.

21. Mao, Y., Moloughney, B.W., Semenciew, R., et Morrison, H. Indian Reserve and Registered Indian Mortality in Canada. Canadian Journal of Public Health, 1992; 83:350-353.

22. Young, T.K. Cardiovascular Disease and Risk Factors Among North American Indians . Winnipeg, MB: Northern Health Research Unit, 1990.

23. Young, T.K. Self-perceived and clinically assessed health status of Indians in northwestern Ontario: Analysis of a health survey. Canadian Journal of Public Health , 1982; 73:272-277.

24. McIntyre, L., Shah, C.P. Prevalence of hypertension, obesity and smoking in three Indian communities in northwestern Ontario. Canadian Medical Association Journal, 1986; 143:345-349.

25. Nair C., Nicholls E. Cardiovascular Disease in Canada . Ottawa, ON: Centre canadien d'information sur la santé, Statistique Canada, 1990.

26. Goldman L., Cook, E.F. The decline in ischemic heart disease mortality rates. Annals of Internal Medicine, 1984; 101:825-836.

27. Nova Scotia-Saskatchewan Cardiovascular Disease Epidemiology Group. Estimation of the incidence of acute myocardial infarction using record linkage. A feasibility study in Nova Scotia and Saskatchewan. Canadian Journal of Public Health, 1989; 80(6):412- 416.

28. Wielgosz, A.T. Establishing surveillance of cardiovascular disease incidence in Canada. Canadian Journal of Cardiology , 1992; 8(3):249-251.

29. Nova Scotia-Saskatchewan Cardiovascular Disease Epidemiology Group. Trends in incidence and mortality from acute myocardial infarction in Nova Scotia and Saskatchewan 1974-1985. Canadian Journal of Cardiology, 1992; 8(3):253-258.

30. Les principaux chercheurs du projet MONICA de l'OMS. The World Health Organization MONICA Project (Monitoring of Trends and Determinants in Cardiovascular Disease): A major international collaboration. Journal of Clinical Epidemiology, 1988; 41:105-114.

31. Gregor, R.D., Guerensey, J.R., Mackenzie, B.R., et coll. Prevalence of ischemic heart disease and its treatment in Halifax County; results of the MONICA survey. Nova Scotia Medical Journal, 1990; 69:146-149.

32. Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P. et coll. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates and case-fatality rates. Circulation, juillet 1994; 90(1):583-612.

33. Johansen, H., Nair, C. et Taylor, G. Rapport inédit.

34. Intercontinental Medical Statistics Canada. Données inédites.

35. Bureau of Chronic Disease Epidemiology, Laboratory Centre for Disease Control, Health Canada. Données inédites.

36. Moore, R. et coll. Economic Burden of Illness in Canada, 1993. Version finale, le 22 juillet 1996, Laboratoire de lutte contre la maladie, Santé Canada.

37. Bureau de l'épidémiologie des maladies chroniques, Laboratoire de lutte contre la maladie. Données inédites.

38. Dawber, T.R. The Framingham Study: The epidemiology of Atherosclerotic Disease. Cambridge, Ma: Harvard University Press, 1980, p.257.

39. National Institutes of Health. Epidemiology and Prevention of Cardiovascular Disease. U.S. Department of Health and Human Services, National Institutes of Health. 1994.

40. Santé Canada. The Canadian Heart Health Initiative: a policy in action. Health Promotion , 1992; 30(4):1-19 (insert).

41. MacLean, D.R., Petrasovits, A., Nargundkar, M., et coll. Canadian heart health surveys; a profile of cardiovascular risk: survey methods and data analysis. Canadian Medical Association Journal, 1992; 146(11, suppl):1969-1974.

42. Canadian Heart Health Surveys Research Group. The Federal-Provincial Canadian Heart Health Initiative. Canadian Medical Association Journal , 1992; 146(6):1-2.

43. Santé Canada. Canadians and Heart Health: Reducing the Risk. Ottawa, ON: Santé Canada, 1995.

44. Santé Canada. Survey on Smoking in Canada. Ottawa, ON; Santé Canada, 1994.

45. Santé Canada. 1994 Youth Smoking Survey, Ottawa, Ministère des Approvisionnements et Services Canada, 1996.

46. Monique-Verschuren ,W.M. Total cholesterol concentration and mortality at a relatively young age; do men and women differ? British Medical Journal, septembre 1995;; 23:311(7008):779-8l3.

47. Lipid Research Clinic Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results 1: Reduction in incidence of coronary heart disease. Journal of the American Medical Association , 1984; 251:351-364.

48. Connelly, P.W., MacLean, D.R., Horlick, L., et coll. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Medical Association Journal, 1992; 146(11, suppl):1977-1987.

49. Canadian Conference on Cholesterol: Final report. Canadian Medical Association Journal, 1988; 139:1-8.

50. Gordon, T., Castelli, W.P., et coll. High density lipoproteins as a protective factor against coronary heart disease. American Journal of Medicine , 1977; 62:707-714.

51. Criqui, M.H., Heiss, G., et Cohn, R. Triglycerides and coronary heart disease mortality: Lipid Research Clinics program follow-up study. American Heart Association 27th Conference on Cardiovascular Disease, 1987.

52. Austin, M.A. Plasma triglyceride as a risk factor for coronary heart disease: The epidemiologic evidence and beyond. American Journal of Epidemiology, 1989; 129:249-259.

53. Lamarche, B., Moorjani, S., Lupien, P.J., et coll. Apolipoprotein A-1 and B and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation, 1996; 94:273-278.

54. Lamarche, B., Tchernof, A., Moorjani, S., et coll. Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation, 1997; 95:69-75.

55. MacMahon, S. et coll. Blood pressure, stroke and coronary hear disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. The Lancet, 1990; 335:765-774.

56. Kannel, W.B. Blood pressure as a cardiovascular risk factor: prevalence and treatment. Journal of the American Medical Association , mai 1996; 22-29; 275(20):1571-6.

57. Joffres, M.R., Hamet, P., Rabkin, S.W., et coll. Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Medical Association Journal , 1992; 146(11, suppl):1997-2005.

58. Kannel, W.B. Cardioprotection and antihypertensive treatment: the key implications of addressing the associated coronary risk factors (the Framingham experience). American Journal of Cardiology, février 1996; 22; 77(6):6B-11B.

59. Kannel, W.B. Framingham Study insights into hypertensive risk of cardiovascular disease. Hypertension Research, septembre 1995; 18l(3):181-96.

60. American Heart Association. The Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology. Benefits and recommendations for physical activity programs for all Americans. Circulation , 1992; 86(1):340-344.

61. Stephens, T., Craig, C.L. The Well-Being of Canadian: Highlights of the 1988 Campbell's Survey . Ottawa, ON, Institut canadien de la recherche sur la condition physique et le mode de vie, 1990.

62. Caspersen, C.J., Merritt, R.K., et Stephens, T. International physical activity patterns: a methodological perspective. Dans Advances in Exercise Adherence , Dishman, R.K. (réd.). Human Kinetics, Champaign, IL, 1994.

63. Haskell, W.L., Montoye, H.J., et Orenstine, D. Physical activity and exercise to achieve health-related physical fitness components. Public Health Reports, 1985; 100:202-212.

64. Fondation des maladies du coeur du Canada. Position Statement on Physical Activity, Ottawa : Fondation des maladies du coeur du Canada, mai 1993.

65. United States Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996.

66. Connolly, V.M., Kesson, C.M. Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. Diabetic Care , mai 1996; 19(5):419-22.

67. Reeder, B.A., Angel, A., Ledoux, M. et coll. Obesity and its relation to cardiovascular disease risk factors in Canadian adults. Canadian Medical Association Journal, 1992; 146(11, suppl):2009-2019.

68. Harris, M.I., Hadden, W.C., Knowler, W.C., et coll. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the U.S. population aged 20-74 years. Diabetes, 1987; 36:523-534.

69. Statistique Canada. 1991 Aboriginal Peoples Survey, Statistique Canada, 1991.

70. Hubert, A.B., Feinleib, M., McNamara, P.M., et coll. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation , 1983; 67:968-977.

71. Larsson, B., Svardsudd, K., Welin, L., et coll. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease; 13-year follow-up of participants in the study of men born in 1913. British Medical Journal, 1984; 288:1401-1404.

72. Canadian Guidelines for Healthy Weights: Promoting Healthy Weights (document de travail), Santé et Bien-être social Canada, Direction générale des services et de la promotion de la santé, Ottawa, 1988.

73. Kannel, W.B. Effect of weight on cardiovascular disease. Amercian Journal of Clinical Nutrition, mars 1996; 63(3 suppl):419S-422S.

74. Verrier, R.L. Life-threatening cardiovascular consequences of anger in patients with coronary heart disease. Cardiology Clinics, mai 1996; 14(2):289-307.

75. Dagenais, G., Université de Montréal., données transmises personnellement.

76. Pershagen, G., Smokeless tobacco. British Medical Bulletin, janvier 1996; 52(1):50-7.

77. Ernst, E. Fibrinogen as a cardiovascular risk factor: meta-analysis and review of the literature. Annals of Internal Medicine 1993; 118:956-63.

78. Perry, I.J. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. The Lancet novembre 1995; 25:346(8987):1395-8.

79. Wilhelmsen, L. Synergistic effects of risk factors. Clinical and Experimental Hypertension, part A , 1990; 12:845-863.

80. MacDonald, S., Joffres, M.P., Stachenko, S.J., et coll. Multiple cardiovascular risk factors in Canadian adults. Canadian Medical Association Journal , 1992; (11, suppl):2021-2029.

81. Wolf, P.A., Cobb, J.L., et D'Agostino, R.B. Epidemiology of stroke. Dams Stroke: Pathophysiology, diagnosis and management . Barnett, JJ (eds). New York, NY: Churchill Livingstone, 1992: 3-29.

82. Lerner, D.J., et Kannel, W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. American Heart Journal , 1986; 111:383-390.

83. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with systolic hypertension. Journal of the American Medical Association , 1991; 265:3255-3264.

84. Lindenstrom, E. Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study. American Journal of Epidemiology, décembre 1995; 15:142(12):1279-90.

85. Donnan, G.A., You, R., Thrift, A., et McNeil, J.J. Smoking as a risk factor for stroke. Cerebrovascular Disease , 1993; 3:129-138.

86. Wolf, P.A., D'Agostino, R., Kannel, et coll. Cigarette smoking as a risk factor for stroke. The Framingham Study. Journal of the American Medical Association, 1988; 259:1025-1029.

87. Shinton, R., et Beevers, G. Meta-analysis of the relation between cigarette smoking and stroke. British Medical Journal , 1989; 298:789-793.

88. Colditz, G.A., Bonita, R., et Stampfer, M.J. Cigarette smoking and the risk of stroke in middle aged women. New England Journal of Medicine, 1988; 318:937-941.

89. Petersen, P., Boysen, G., Godtfredsen, J., et coll. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complicatons in atrial fibrillation. The Lancet, 1989; 1:175-179.

90. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigations. The effect of low dose on the risk of stroke in patients with nonrheumatic atrial fibrillation. New England Journal of Medicine, 1990; 323:1505-1511.

91. Preliminary report of the stroke prevention in atrial fibrillation study. New England Journal of Medicine, 1990; l322:863-868.

92. Koeford, B.G. Atrial Fibrillation and apoplexy - risks and prevention. Nord Med , juin 1996; 111(6):171-5.

93. Sorenson, P.S., Marquadsen, J., Pederson, J., et coll. Long-term prognosis and quality of life after reversible cerebral ischemic attacks. Acta Neurologica Scandinavica, 1989; 79:204-213.

94. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effects of carotid endarterectomy in symptomatic patients with high-grade stenosis. New England Journal of Medicine , 1991; 325:445-453.

95. Barnett, H.J.M. Drug and surgical issues in stroke prevention.. Cerebrovascular Disease, 1994; 1(4 suppl):16-25.

96. Feinberg, W.M., Albers, G.W., Barnett, H.J.M., et coll. Guidelines for the management of transient ischemic attacks. From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke, 1994; 25:1320.

97. Wannamethee, G., et Shaper, A.B. Physical activity and stroke in British middle-aged men. British Medical Journal , 1992; 304:597-601.

98. Fletcher, G.F., Blair, S.N., Blumental, J., et coll. Statement on Exercise. Benefits and recommendation for the physical activity programs for all Americans. Circulation , 1992; 86:340-344.

99. Tuomilehto, J., Rastenyte, D., Jousilahti, P., et coll. Diabetes mellitus as a risk factor for death from stroke. Prospective study of a middle-aged Finnish population. Stroke, février 1996; 27(2):202-5.

100. Heinrich, J. Fibrinogen and cardiovascular risk. Journal of Cardiovascular Risk , juin 1995; 2(3):197-205.

101. Bogousslavsky, J., Garazi, S., Jeanrenaud, X., et coll. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study, Lausanne Stroke with Paradoxical Embolus Study Group. Neurology, 1996 May; 46(5):1301-5.

102. Hunink, M.G.M., Goldman, L., Tosteson, A.N.A., et coll. The Recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. Journal of the American Medical Association , 1997; 277:535- 542.

103. Wong, T., et Wilkins, K. How many deaths from major chronic disease could be prevented: Chronic Disease in Canada, 1990; 11:573-575.

104. Farquhar, J.W. Effects of community wide education on cardiovascular disease risk factors: The Stanford Five-City Project. Journal of the American Medical Association, 1990; 264(3):359-365.

105. Puska, P., Tuomilehto, J., et coll.. The North Karelia Project: Evaluation of a comprehensive community programme for control of cardiovascular disease in 1972-77 in North Karelia, Finland . Copenhagen, Denmark, World Health Organization/EURO Monograph Series, 1981.

106. Vartiainen, E., Puska, P., Pelckanen, J., et coll. Changes in risk factors explain changes in mortality from ischemic heart disease in Finland. British Medical Journal , 1994; 309:23-27.

107. Shea, S., and Basch, C.E. A review of the five major community based cardiovascular disease prevention programs. Part 1: Rationale, design, and theoretical framework. American Journal of Health Promotion, 1990; 4(3):302-313.

108. Groupe de travail fédéral-provincial sur la prévention et le contrôle des maladies cardio-vasculaires. Promotion de la santé cardio-vasculaire au Canada : Pleins feux sur le cholestérol, Ottawa, Ontario, 1992.

109. Santé et Bien-être social Canada. La santé pour tous : plan d'ensemble pour la promotion de la santé, Ottawa, Ontario, Santé et Bien-être social Canada, 1986.

110. La Déclaration de Victoria sur la santé cardio-vasculaire. Comité consultatif, Conférence internationale sur la santé cardio-vasculaire (Victoria, Canada, le 28 mai 1992), Santé Canada, Ottawa, 1992.

111. La Déclaration de Catalogne : Investir dans la santé du coeur. Comité consultatif, 2^e Conférence internationale sur la santé du coeur (Barcelone, Espagne, juin 1995), Département de la Santé et de la Sécurité sociale, Gouvernement autonome de Catalogne, Barcelone, 1996.

112. Kalache, A., et Aboderin, I. Stroke: the global burden. Health Policy and Planning, 1995: 10(1):1-21.

113. Gordon, M. Monograph Series on Aging-related Disease: III. Stroke(Cerebrovascular Disease). Chronic Disease in Canada , 1993; 14(3):64-89.

114. Mayo, N.E. Hospitalization and case-fatality rates for stroke in Canada from 1982 through 1991. The Canadian collaborative study group of stroke hospitalizations. Stroke, 1996; 27:1215-20.

115. Petrasovits, A., et Nair, C. Epidemiology of stroke in Canada. Health Reports 1994; 6:39-44.

116. Asplund, K., Bonita, R., Kuulasmaa, K., et coll. Multinational comparisons of stroke epidemiology. Evaluation of case ascertainment in the WHO MONICA Stroke Study. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke, 1995; 26:355- 60.

117. Thorvaldsen, .P. et coll. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke, 1995; 26:361-7.

118. Whisnant, J.P.. The decline of stroke. Stroke , 1984; 15:160-8.

119. Brown, R.D., Whisnant, J.P., Sicks, J.D., et coll. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke, 1996; 27:373-80.

120. Modan, B., et Wagener, D.K.. Some epidemiological aspects of stroke: mortality/ morbidity trends, age, sex, race, socioeconomic status. Stroke, 1992; 23:1230-6.

121. Wolf, P.A., D'Agostino, R.B., O'Neal, M.A., et coll. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke, 1992; 23:1551-5.

122. Gillum, R.F. Cerbrovascular disease morbidity in the United States, 1970-1983. Age, sex, region, and vascular surgery. Stroke , 1986; 17:656-61.

123. Bonita, R., et Beaglehole, R. Monitoring stroke. An international challenge. Stroke, 1995; 26:541-2.

124. Garraway, W.M., Whisnant, J.P. et Drury, I. The continuing decline in the incidence of stroke. Mayo Clinic Proceedings, 1983; 58:520-3.

125. Gillum, R.F., Gomez-Marin, O., Kottke, T.E., et coll. Acute stroke in a metropolitan area, 1970 and 1980. The Minnesota Heart Survey. Journal of Chronic Disease, 1985; 38:891-8.

126. Kotila, M. Declining incidence and mortality of stroke? Stroke, 1984;15:255-9.

127. Folsom, A.R., et coll. Improvement in hypertension detection and control from 1973-1974 to 1980-1981. The Minnesota Heart Survey experience. Journal of the American Medical Association, 1983; 250:916-21.

128. Garraway, W.M., Whisnant, J.P., Furland, A.J., et coll. The declining incidence of stroke. New England Journal of Medicine, 1979; 300:449-52.

129. Broderick, K.J.P., Phillips, S.J., Whisnant, J.P., et coll. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke , 1989; 20:577-82.

130. Kuller, L.H. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke, 1989; 20:841-3.

131. Mayo, N.E., et coll. Changing rates of stroke in the province of Quebec, Canada: 1981-1988. Stroke, 1991; 22:590-5.

132. Terent, A. Increasing incidence of stroke among Swedish women. Stroke, 1988; 19:598-603.

133. Siesjo, B.K., Zhao, Q., Pahlmark, K, et al Glutamate, calcium and free radicals as mediators of ischemic brain damage. Annals of Thoracic Surgery, 1995; 59:1316-1320.

134. Obrenovitch, T.P. The ischemic penumbra: Twenty years on. Cerebrovascular and Brain Metabolism Reviews, 1996; 7:297-323.

135. Ginsberg, M.D. Injury mechanisms in the penumbra: approaches to neuroprotection in acute ischemic stroke. Cerebrovascular Disease, 1997; 7(suppl 2):7-12.

136. Baron, J.C., von-Kummer, R. et del-Zoppo, G.J. Treatment of acute stroke. Challenging the concept of a rigid and universal time window. Stroke, 1995;2 6:2219- 2221.

137. Giroux, C., et Scatton, B. Ischemic stroke: treatment on the horizon. Eur Neurol , 1996; 36:61-64.

138. Wilgren, N. Neuroprotection in late clinical development - a status report. Cerebrovascular Disease, 1997; 7(supp 2):13-17.

139. Langhorne, P., Williams, B.O., Gilchrist, W., et coll. Do stroke units save lives? The Lancet, 1993; 342:395-398.

140. Kalra, L. The influence of stroke unit rehabilitation on functional recovery from stroke. Stroke, 1994; 25:821-825.

141. Adams, H.P. Jr. Investigation of the patient with ischemic stroke. Cerebrovascular Disease , 1991; 1Suppl.1:54-60.

142. Donnan, G.A. Investigations of patients with stroke and transient ischemic attacks. The Lancet, 1992; 339:473-477.

143. Feinberg, W.M., et coll. Guidelines for the management of transient ischemic attacks: From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks of the Stroke Council of the American Heart Association. Stroke, 1994; 25:1320.

144. Adams, H.P., Brott, T.G., Crowell, R.M., et coll. Guidelines for the management of patients with acute ischemic stroke: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke, 1994; 25:1901-1914.

145. Adams, H.P., Brott, T.G., Crowell, R.M., et coll. Guidelines for the management of patients with acute ischemic stroke. Stroke, 1994; 25:1901-1914.

146. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine , 1995; 3 33:1581-1587.

147. Rose, G. Strategy of prevention: lessons from cardiovascular disease. British Medical Journal , 1981; 28l2:1847-1851.

148. MacMahon, S., et Rodgers, A. Blood pressure, antihypertensive treatment and stroke risk. Journal of Hypertension , 1994; 12(suppl.10):S5-14.

149. Phillips, S.J. Pathophysiology and management of hypertension in acute ischemic stroke. Hypertension , 1994; 23:131-136.

150. Phillips, S.J., et Whisnant, J.P. On behalf of the National High Blood Pressure Education Program. Hypertension and the brain. Archives of Internal Medicine, 1992; 152:938-945.

151. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) The Lancet, 1994; 344:1383-1389.

152. Donnan, G.A., et coll. Smoking as a risk factor for stroke. Cerebrovascular Disease, 1993; 3:129-138.

153. Silagy, C., Mant, D., Fowler, G. et Lodge, M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. The Lancet , 1994; 343:139-142.

154. Sacco, R.L., Lin, I.F., Boden-Albala, D.E., et coll. Alcohol and the risk of ischemic stroke: Verification of a J-shaped relationship from the Northern Manhattan Stroke Study. Stroke, 1997; 28:250.

155. Shinton, R., et Beevers, G. Lifelong exercise and stroke. British Medical Journal, 1993; 307:231-234.

156. Antiplatelet Trialists' collaboration. Collaborative overview of randomised trials of Antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged Antiplatelet therapy in various categories of patients. British Medical Journal, 1994; 308:81-106.

157. International Stroke Trial Collaborative Group. The International Stroke Trial (IST); a randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patientswith acute ischaemic stroke. The Lancet, 1997, in press.

158. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: a randomised placebo-controlled trial of early aspirin use in 19,975 patients with acute ischaemic stroke. The Lancet, 1997, in press.

159. Diener, H., et coll. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci , 1996; 143:1-13.

160. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet, 1996; 348:1329-1338.

161. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives of Internal Medicine , 1994; 154:1449-1457.

162. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. The Lancet, 1993; 342:1255-1262.

163. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. New England Journal of Medicine, 1995; 333:5-10.

164. Turpie, A.G.G., Colly, L.P., Heijboer, H., et coll. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. New England Journal of Medicine , 1993; 329:524-529.

165. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine, 1991; 325:445-453.

166. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-90%) or with mild (0-29%) carotid stenosis. The Lancet, 1991; 337:1235-1243.

167. Asymptomatic Carotid Atherosclerosis Group. Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis. Journal of the American Medical Association , 1995; 273:1421-1428.

168. Perry, J.R., Szalai, J.P., et Norris, J.W., for the Canadian Stroke Consortium. Consensus against both carotid endarterectomy and routine screening for asymptomatic carotid artery stenosis. Archives of Neurology , 1997; 54:25-28.

[Table des matières] [Précédente]